Perioperative Management Rheumatic Diseases
Publication Date: June 20, 2022
Key Points
Key Points
- Patients with rheumatic diseases undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA) are at increased risk for periprosthetic joint infection.
- Appropriate management of antirheumatic medication in the perioperative period may provide an important opportunity to mitigate risk.
- Nonbiologic disease-modifying antirheumatic drugs may be continued throughout the perioperative period in patients with rheumatic diseases who are undergoing elective THA and TKA.
- Biologic medications should be withheld as close to 1 dosing cycle as scheduling permits prior to elective THA and TKA and restarted after evidence of wound healing, typically 14 days, for all patients with rheumatic diseases.
Treatment
...Treatmen...
...edications To CONTINUE Through Surgery...
...dications To WITHHOLD Prior To Surgery*...
...ions Included in the Guideline...
...Summary of...
...the current dose of methotrexate, leflunomide,...
...l current biologic agents prior to surge...
...ofacitinib for at least 3 days prio...
Continue the current dose of mycophenolate m...
...rrent dose of mycophenolate mofetil, azath...
...rt biologic therapy in patients fo...
...current daily dose of glucocorticoids in a...
a See Table 3